This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.

This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.

Are you testing for MSI-H/dMMR in your patients with advanced endometrial cancer? Listen in as Drs. Robert Coleman, Susana Campos, and Ana Oaknin break down the progress being made in biomarker testing and immunotherapy treatment for these patients.

This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.

The use of noninvasive tools in NAFLD/NASH has become more prevalent over the last several years, with increased availability of imaging and serum-based tools. A forum of experts convened to discuss optimal use of these tools in NAFLD/NASH using a series of clinical assertion statements. These statements covered screening patients with diabetes, applicability of liver enzymes in determining fibrosis stage, use of transient elastography and blood-based tools, such as the Enhanced Liver Fibrosis test, and potential genetic testing. Here, Drs Jacobson and Younossi summarize the research and discussion points from the forum.

This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.

This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.

This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.

This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.

This program discusses the expanding use of ICIs to treat patients with early-stage NSCLC. The education addresses newly approved and investigational perioperative neoadjuvant and adjuvant therapy with ICIs. It includes scientific rationale driving research, clinical trial surrogate endpoints, identification of predictive biomarkers, mechanisms of disease resistance, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges.